

ANP to present at Several Upcoming Virtual Conferences

Antisense Therapeutics Limited (ASX: ANP | US OTC: ATHJY | FSE: AWY) is pleased to announce that the Company will present at several upcoming virtual conferences.

- 3rd Annual Neuromuscular Drug Development Summit (1st - 3rd December) – Digital Event

Date: Friday 4th December @ 1.50am AEDT

Website: <https://neuromuscular-drugdevelopment.com/about/about-event/>

"...With emphasis on SMA, DMD, DM1 and ALS, the summit will put the spotlight on developing drugs which target the core mechanisms of disease. Across 3 packed days, 22 thought-leaders will share their insights enabling you to: validate clinically meaningful endpoints to prove drug efficacy; optimize your clinical trial design to define the right patient populations and dosing regimens and evaluate approaches to integrate biomarkers into your programs..."

- Phar-East Pharma & Biotech Festival - Singapore

Date: Tuesday 8th December @ 2.30pm AEDT

Website: <https://www.terrapiinn.com/exhibition/phar-east/our-story.stm>

"...Phar-East is a premium closed-door conference held annually in Singapore for the Asian Pharma and Biotech industry. The 2019 edition took place in March and continued to set a strong precedent with an attendance of targeted delegates, brought together from 29 countries, along with the 120 specialist speakers who captivated the audience throughout both days..."

- 10th Anniversary Virtual Conference – Little Steps Association for Duchenne-Becker Patients - Israel

Date: Wednesday 9th December 4.40am AEDT

Website: <https://www.littlesteps.org.il/english/>

"...Little Steps is an Israeli nonprofit organization founded in 2010 by parents of children with DMD/BMD. Our goal is to extend life-expectancy and improve the treatment for DMD/BMD patients. In recent years, Little Steps Association has invested over 2 million NIS in funding preclinical and clinical studies aimed at finding a medication for the disease. The Little Steps association's collaborations with treatment centers and research companies have led to impressive achievements. Most clinical studies in the world are conducted in Israel and about 60% of the sick children in Israel receive innovative treatments, as part of research or approval of new medications..."

"Presenting at these conferences is an important opportunity to highlight the continued advancement of the Company's drug ATL1102 for the treatment of Duchenne muscular dystrophy and its progress towards Phase IIB clinical trials in Europe", said Mark Diamond, CEO.

This announcement has been authorised for release by the Managing Director.

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY | FSE: AWY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.